Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00744276 · ClinicalTrials.gov registry record · Phase 2
A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease
A Phase 2 study, sponsored by FemmePharma Global Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00744276 is a Phase 2 study that has completed, run by FemmePharma Global Healthcare. The registered enrollment target is 60 participants.
The verdict
NCT00744276, a Phase 2 study, has completed, sponsored by FemmePharma Global Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of three doses of topically applied danazol compared to placebo in subjects with pain associated with fibrocystic breast disease and to determine the appropriate clinical dose for future studies.
Interventions
- DRUG Placebo
- DRUG danazol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00744276
The ClinicalTrials.gov registry entry for NCT00744276 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is FemmePharma Global Healthcare, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00744276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00744276 about?
NCT00744276 is a clinical study titled "A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease". The purpose of this study is to determine the safety of three doses of topically applied danazol compared to placebo in subjects with pain associated with fibrocystic breast disease and to determine the appropriate clinical dose for future studies.
What is the current status of trial NCT00744276?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2007-01. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00744276?
The interventions under investigation include: Placebo (DRUG), danazol (DRUG).
Who is sponsoring clinical trial NCT00744276?
This trial is sponsored by FemmePharma Global Healthcare, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.